Lisdexamfetamine Dimesylate

Amneal Pharmaceuticals has received an abbreviated new drug application from the FDA for its lisdexamfetamine dimesylate capsules to treat ADHD in patients aged 6 years and older and moderate to severe binge-eating disorder in adults.

Lisdexamfetamine significantly improved outcomes among adults with ADHD and comorbid sluggish cognitive tempo, according to results of a crossover trial published in Journal of Clinical Psychiatry.

A combination of medication and behavioral treatments may benefit multiplex families where both children and their mothers have ADHD, according to study results published in Journal of Clinical Psychiatry.